Search Results for “AI” – Page 46 – media

Charles River and Related Sciences partner for AI drug platform

Charles River Laboratories International has signed a multi-programme collaboration agreement with Related Sciences (RS) for the artificial intelligence (AI)-powered drug platform, Logica. Last year, Charles River and Valo Health unveiled Logica, a solution that leverages the AI-powered Valo Opal Computational Platform, along with Charles River’s preclinical expertise. Logica will be used on multiple previously undrugged targets within the RS portfolio. RS will collaborate with the teams from both Charles River and Valo Health to deploy Logica to discover significant new medicines. These medicines will be used to meet unmet requirements across disease areas including autoimmunity, cancer immunotherapy and inflammatory diseases. Charles River senior vice-president and chief scientific officer Julie Frearson stated: “Logica’s unique platform, which combines AI/machine learning (ML)-enabled in silico discovery, high-powered DNA-encoded libraries and traditional screening techniques, has the capability to accelerate the drug discovery and development pipeline, transforming a target to a candidate in just over two ...
- Source: drugdu
- 195
- September 18, 2023
NICE recommends use of Vydura for acute migraines on the NHS

Adults in England and Wales with acute migraines will now have access to a new treatment after the National Institute for Health and Care Excellence (Nice) recommended Pfizer’s Vydura for use on the NHS. In May, NICE recommended the drug – with the generic name rimegepant – for the prevention of migraines. At the time, NICE said up to 145,000 people would benefit from the treatment, though the drug was only permitted for use as a fourth-line treatment option. As per the most recent draft guidance, the drug has now been recommended for adults who do not respond to two previous migraine medicines, called triptans. Although this means Vydura is still not recommended for primary use, the move will help an additional 13,000 people access the treatment, NICE said. Patients who do not benefit from taking nonsteroidal anti-inflammatory drugs or paracetamol have also been endorsed to take the treatment in ...
- Source: drugdu
- 113
- September 16, 2023
Acelyrin’s Lead Asset Izokibep Fails in Late-Stage Hidradenitis Suppurativa Trial

By Tristan Manalac Pictured: Close-up of a skin lesion in a patient with hidradenitis suppurativa/iStock, krblokhin Top-line data from a Phase IIb/III trial showed that Acelyrin’s investigational IL-17A inhibitor izokibep fell short of its primary endpoint in patients with hidradenitis suppurativa, a chronic inflammatory skin condition, the company announced Monday. In patients who were being treated with 160-mg izokibep once-weekly, 39% demonstrated at least a 75% decrease in the hidradenitis suppurativa clinical response (HiSCR75) score at 16 weeks, while 29% of placebo comparators achieved a similar level of clinical response. This did not result in a significant treatment effect, with a p-value of 0.3278, according to the company’s announcement. Even the twice-weekly izokibep schedule was unable to significantly distinguish itself from placebo, with only 34% of patients achieving HiSCR75 at 16 weeks. These findings were calculated using a non-responder imputation (NRI) method. Acelyrin’s shares tanked 64% in after-hours trading in ...
- Source: drugdu
- 109
- September 14, 2023
AstraZeneca Signs AI-Powered Drug Discovery Pact with Verge

By Tristan Manalac AstraZeneca, through its rare disease division Alexion, has entered into a multi-target agreement with Verge Genomics to discover and develop drugs against novel targets in rare neurodegenerative and neuromuscular diseases, the companies announced Friday. Under the agreement, Alexion will make a $42 million payment in upfront fees, as well as equity and near-term investments. Counting milestones, the four-year collaboration can yield up to $840 million for Verge, plus potential royalties down the line. Alongside the drug discovery pact, AstraZeneca will also take an equity position in Verge. In return, Alexion will gain access to the California biotech’s proprietary full-stack CONVERGE platform, which applies machine learning to human tissue data in order to identify novel disease targets that have a high probability of yielding clinical success. Friday’s partnership will apply the AI-driven approach to several yet-undisclosed rare neurodegenerative and neuromuscular conditions. Alexion will have the option to select ...
- Source: drugdu
- 196
- September 12, 2023
J&J dumps high-dose Opsumit trial upon failure in rare type of pulmonary hypertension

Johnson & Johnson’s plan to expand decade-old pulmonary hypertension med Opsumit has hit a snag.J&J’s Janssen has decided to stop a phase 3 trial for a 75-mg dose of macitentan in patients with chronic thromboembolic pulmonary hypertension (CTEPH). The company pulled the plug after an independent data monitoring committee performed an interim analysis and figured the trial wouldn’t succeed. Macitentan, given at 10 mg daily, won approval in 2013 under the brand name Opsumit for treating pulmonary arterial hypertension (PAH). PAH and CTEPH are slightly different diseases, but both feature abnormally high blood pressure in the arteries of the lungs. The results from the high-dose trial, dubbed MACiTEPH, won’t affect the marketed product, J&J said. Separately, J&J is trying to show that the higher dose works better than the FDA-approved 10-mg version in PAH. That study, coded UNISUS, remains ongoing with an estimated primary completion date next month, according to ...
- Source: drugdu
- 103
- September 9, 2023
BMS Accused by HMO of Patent Fraud to Allegedly Sustain Pomalyst Monopoly

By Tristan Manalac Pictured: BMS office in California/iStock, hapabapaBlue Cross and Blue Shield of Louisiana on Tuesday filed a class action lawsuit against Bristol Myers Squibb, accusing the pharma giant of unlawfully extending the market exclusivity for its multiple myeloma drug Pomalyst (pomalidomide), according to Reuters. The Baton Rouge-based health maintenance organization is being joined by HMO Louisiana, a subsidiary of Blue Cross and Blue Shield of Louisiana. The plaintiffs are representing a proposed class of entities in the U.S. and its territories that paid for or reimbursed Pomalyst from October 2020. In the 151-page complaint, the not-for-profit health insurance company alleged that BMS and its subsidiary Celgene committed patent fraud by misrepresenting and concealing data regarding Pomalyst’s properties, formulations and uses that had already been publicly available. The pharma companies also “abused the federal judicial system” by launching a barrage of “sham lawsuits” against generics companies that were trying ...
- Source: drugdu
- 184
- September 9, 2023
Researchers receive $2.5 million award to develop a tailored treatment for glioblastoma

A multidisciplinary team of investigators from the UCLA Jonsson Comprehensive Cancer Center was awarded a $2.5 million Translational Team Science Award from the Department of Defense to develop a tailored treatment for glioblastoma, a deadly brain tumor with limited treatment options. The team -; including David Nathanson, associate professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, Benjamin Ellingson, director of the UCLA Brain Tumor Imaging Laboratory and professor of radiological sciences, and Dr. Timothy Cloughesy, professor of neuro-oncology -; plan to target the epidermal growth factor receptor, a protein that is mutated in about 60% of people diagnosed with glioblastoma. Previous attempts have had limited success improving patient outcomes due to drugs’ inability to cross the blood-brain barrier and target genetic alterations in the protein that are unique to glioblastoma. To overcome these obstacles, the researchers have developed ERAS-801, a brain-penetrant inhibitor that ...
- Source: drugdu
- 108
- September 7, 2023
New UK study suggests brain fog after COVID-19 is linked to blood clots

A new UK study led by a research team from the University of Oxford and the University of Leicester has suggested that blood clots in the brain or the lungs could potentially explain common symptoms of long COVID. The post-hospitalisation COVID-19 study (PHosp-COVID), published in Nature Medicine, found that people admitted to hospital due to COVID-19 had higher levels of the fibrinogen protein and protein fragment D-dimer, which can cause excess clotting. Excess blood clotting was found to be a possible cause for symptoms like brain fog and fatigue in long COVID. Previous research has found that blood clotting can cause a lack of blood supply to the brain or cause fatigue, which both can cause cognitive problems. People with long COVID can have a wide range of symptoms that last weeks, months, or even years after having a SARS-CoV-2 infection, and for some, it can result in disability or ...
- Source: drugdu
- 189
- September 7, 2023
Years after $2B buyout, Nestlé ditches Aimmune’s peanut allergy drug Palforzia

After lackluster sales dampened the initial enthusiasm that came with a $2.1 billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. Nestlé has divested Palforzia to U.S.-based allergy specialist Stallergenes Greer for an undisclosed sum, the food giant said Tuesday. The transaction closed when the two companies signed the agreement. Nestlé will receive milestone payments and royalties from Stallergenes Greer. The deal comes later than expected. Back in November, Nestlé announced a strategic review of Palforzia, citing slower-than-expected uptake by patients and doctors. At that time, the review was expected to be done in the first half of 2023. Palforzia became the first drug approved by the FDA for peanut allergy in children in January 2020. Back then, Evaluate Pharma projected that the drug could reach $1.28 billion in sales by 2024. Seeing Palforzia’s value in its food allergy portfolio, Nestlé in August 2020 ...
- Source: drugdu
- 159
- September 7, 2023
New Biomarker Tests Aid Quick, Accurate Diagnosis of Alzheimer’s Disease

By Claire Jarvis Pictured: Close-up of an arm receiving a blood draw/iStock, montiannoowong Prior to the approval of effective therapies for Alzheimer’s disease, there was little need for biomarker tests. Now, with Eisai and Biogen’s anti-amyloid drug Leqembi on the market and approval of Eli Lilly’s donanemab expected to follow soon, the pipeline of Alzheimer’s drugs is expanding and the development of tests to detect the disease is accelerating. With Leqembi’s full approval, the Centers for Medicare and Medicaid Services (CMS) has instituted broader coverage of the drug—with stipulations. To ensure reimbursement, physicians must participate in a qualified registry and patients must be diagnosed with mild cognitive impairment or mild Alzheimer’s disease dementia with evidence of beta-amyloid deposits. To help facilitate this, CMS proposed in July 2023 to increase its coverage of PET scans to detect these amyloid plaques—however, cheaper and faster diagnostic methods are still being developed. The past ...
- Source: drugdu
- 190
- September 6, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.